Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OSUR
HOLDOraSure Technologies, Inc. · Healthcare · United States · $273M · Avg Vol: $2M/d
COMPANY DESCRIPTION
OraSure Technologies, Inc. develops, manufactures, and markets a broad range of diagnostic products and collection devices, primarily focused on oral fluid technology for infectious diseases like HIV and COVID-19, and substance abuse. The company holds a competitive edge through its proprietary oral fluid collection platforms and established market presence in point-of-care diagnostics, catering to both clinical and consumer markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 387.5M | 405.5M | 185.8M | 115.0M | -33.3% | 113.0M | 119.7M | 127.8M | 5.4% |
| EPS | -0.25 | 0.73 | -0.26 | -0.94 | — | -1.05 | -0.70 | -0.50 | — |
| Shares | 72.7M | 73.5M | 74.6M | 70.4M | -3.2% | 68.8M | — | — | — |
| Debt | 12.5M | 13.5M | 14.6M | 13.2M | 1.7% | 12.7M | — | — | — |
| Equity | 364.4M | 430.7M | 410.3M | 340.8M | -2.2% | — | — | — | — |
| Op CF | -47.2M | 141.6M | 27.4M | -49.0M | -80.7% | -43.2M | — | — | — |
| Inv CF | 21.1M | 66.2M | -39.0M | -6.8M | — | — | — | — | — |
| Fin CF | -3.8M | -3.0M | -4.2M | -16.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OSUR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OSUR | OraSure Technologies, Inc.(you) | $273M | 48 | HOLD |
| SMTI | Sanara MedTech Inc. | $234M | 60 | HOLD |
| ANGO | AngioDynamics, Inc. | $562M | 58 | HOLD |
| KRMD | KORU Medical Systems, Inc. | $176M | 26 | SELL |
| EMBC | Embecta Corp. | $195M | 74 | BUY |
| DXR | Daxor Corporation | $61M | 43 | HOLD |
| AZTA | Azenta, Inc. | $1.3B | 44 | HOLD |
| STAA | STAAR Surgical Company | $1.2B | 56 | HOLD |
| ATRC | AtriCure, Inc. | $1.8B | 48 | HOLD |
| BLFS | BioLife Solutions, Inc. | $1.5B | 56 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%